| 1 |
Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation[J]. J Heart Lung Transplant, 2011，30(3): 252-269.
|
| 2 |
Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation[J]. J Heart Lung Transplant, 2013，32(12)：1147-1162.
|
| 3 |
Michaels PJ, Espejo ML, Kobashigawa J, et.aj. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease[J]. J Heart Lung Transplant, 2003，22(1)：58-69.
|
| 4 |
Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group: the International Society for Heart Transplantation[J]. J Heart Transplant, 1990，9(6)：587-593.
|
| 5 |
Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants[J]. J Heart Lung Transplant, 2006，25(2)：153-159.
|
| 6 |
Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection[J]. J Heart Lung Transplant, 2005，24(11)：1710-1720.
|
| 7 |
Crespo-Leiro MG, Veiga-Barreiro A, Doménech N, et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis[J]. Am J Transplant, 2005，5(10)：2560-2564.
|
| 8 |
Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications[J]. J Heart Transplant, 1989，8(6)：430-443.
|
| 9 |
Loupy A, Cazes A, Guillemain R, et al. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy[J]. Am J Transplant, 2011，11(7)：1478-1487.
|
| 10 |
Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection[J]. J Heart Lung Transplant, 2009，28(8)：781-784.
|
| 11 |
Abrams J, Amir O, Etheridge WB, et al. Histologic findings proving the existence of humoral rejection in a cardiac allograft[J]. Cardiovasc Pathol, 2007，16(1)：38-42.
|
| 12 |
Chantranuwat C, Qiao JH, Kobashigawa J, et al. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence[J]. Appl Immunohistochem Mol Morphol, 2004，12(2)：166-171.
|
| 13 |
Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers[J]. Am J Transplant, 2005，5(11)：2778-2785.
|
| 14 |
Kfoury AG, Stehlik J, Renlund DG, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns[J]. J Heart Lung Transplant, 2006，25(11)：1277-1282.
|
| 15 |
Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection[J]. Am J Transplant, 2009，9(9)：2075-2084.
|
| 16 |
Behr TM, Richter K, Fischer P, et al. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A[J]. Transplant Proc, 1998，30(5)：1920-1921.
|
| 17 |
Hammond EH, Hansen JK, Spencer LS, et al. Vascular rejection in cardiac transplantation: histologic, immunopathologic, and ultrastructural features[J]. Cardiovasc Pathol, 1993，2(1)：21-34.
|
| 18 |
Smith JD, Danskine AJ, Rose ML, et al. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes[J]. Transplantation, 1992，53(6)：1358-1362.
|
| 19 |
Reed EF, Hong B, Ho E, et al. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease[J]. Transplantation, 1996，61(4)：566-572.
|
| 20 |
Rose ML. Role of MHC and non-MHC alloantibodies in graft rejection[J]. Curr Opin Organ Transplant, 2004，9(1)：16-22.
|
| 21 |
Faulk WP, Rose M, Meroni PL, et al. Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts[J]. Hum Immunol, 1999，60(9)：826-832.
|
| 22 |
Nath DS, Ilias Basha H, Tiriveedhi V, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy[J]. J Heart Lung Transplant, 2010，29(11)：1277-1285.
|
| 23 |
Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation[J]. Transplantation, 2001，71(7)：886-892.
|
| 24 |
Zhang Q, Cecka JM, Gjertson DW, et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation[J]. Transplantation, 2011，91(10)：1153-1158.
|
| 25 |
Lones MA, Czer LS, Trento A, et al. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients[J]. J Heart Lung Transplant, 1995，14(1 pt 1)：151-162.
|
| 26 |
Fedrigo M, Gambino A, Tona F, et al. Can C4d immunostaining on endomyocardial biopsies be considered a prognostic biomarker in heart transplant recipients？[J]. Transplantation, 2010，90(7)：791-798.Erratum in: Transplantation, 2011，15，91(1)：135.
|
| 27 |
Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease[J]. J Immunol, 2004，172(9)：5143-5148.
|
| 28 |
Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation[J]. J Heart Lung Transplant, 2001，20(3)：316-321.
|
| 29 |
Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes[J]. J Heart Lung Transplant, 2009，28(5)：417-422.
|
| 30 |
Mousseaux E, Farge D, Guillemain R, et al. Assessing human cardiac allograft rejection using MRI with Gd-DOTA[J]. J Comput Assist Tomogr, 1993，17(2)：237-244.
|
| 31 |
Butler CR, Thompson R, Haykowsky M, et al. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review[J]. J Cardiovasc Magn Reson, 2009，11(1)：7.
|
| 32 |
Sasaguri S, LaRaia PJ, Fabri BM, et al. Early detection of cardiac allograft rejection with proton nuclear magnetic resonance[J]. Circulation, 1985，72(3 pt 2)：II231-II236.
|
| 33 |
Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling[J]. Am J Transplant, 2006, 6(1)：150-160.
|
| 34 |
Starling RC, Pham M, Valantine H，et al. Molecular testing in the management of cardiac transplant recipients: initial clinical experience[J]. J Heart Lung Transplant, 2006, 25(12)：1389-1395.
|
| 35 |
Khush KK, Patel J, Pinney S, et al. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study[J]. Am J Transplant, 2019，19(10)：2889-2899.
|
| 36 |
Agbor-Enoh S, Shah P, Tunc I, et al. Cell-free DNA to detect heart allograft acute rejection[J]. Circulation, 2021，143(12)：1184-1197.
|
| 37 |
Holzhauser L, Clerkin KJ, Fujino T, et al. Donor-derived cell-free DNA is associated with cardiac allograft vasculopathy[J]. Clin Transplant, 2021，35(3)：e14206
|
| 38 |
Afzal A, Alam A, van Zyl JS, et al. Observed elevated donor-derived cell free DNA in orthotopic heart transplant recipients without clinical evidence of rejection[J]. Clin Transplant, 2022，36(3)：e14549.
|
| 39 |
Miller DV, Roden AC, Gamez JD, et al. Detection of C4d deposition in cardiac allografts: a comparative study of immunofluorescence and immunoperoxidase methods[J]. Arch Pathol Lab Med, 2010，134(11)：1679-1684.
|
| 40 |
Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis[J]. Science, 1995，270(5234)：286-290.
|
| 41 |
Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients[J]. J Heart Lung Transplant, 2010，29(8)：914-956.
|
| 42 |
Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin[J]. Clin Transplant, 2006，20(4)：476-484.
|
| 43 |
Dall’Amico R, Montini G, Murer L, et al. Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection[J]. Int J Artif Organs, 2000，23(1)：49-54.
|
| 44 |
Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis[J]. J Heart Lung Transplant, 2006，25(3)：283-288.
|
| 45 |
Barr ML, Baker CJ, Schenkel FA, et al. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation[J]. Clin Transplant, 2000，14(2)：162-166.
|
| 46 |
Kyle RA, Rajkumar SV. Multiple myeloma[J]. N Engl J Med, 2004，351(18)：1860-1873. Erratum in: N Engl J Med, 2005，352(11)：1163.
|
| 47 |
Garrett HE Jr, Duvall-Seaman D, Helsley B, et al. Treatment of vascular rejection with rituximab in cardiac transplantation[J]. J Heart Lung Transplant, 2005，24(9)：1337-1342.
|
| 48 |
Keren A, Hayes HM, O’Driscoll G. Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab[J]. Transplant Proc, 2006，38(5)：1520-1522.
|
| 49 |
Balfour IC, Fiore A, Graff RJ, et al. Use of rituximab to decrease panel-reactive antibodies[J]. J Heart Lung Transplant, 2005，24(5)：628-630.
|
| 50 |
Woodside KJ, Lick SD. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection[J]. J Heart Lung Transplant, 2007，26(7)：750-752.
|
| 51 |
Wang H, Jiang J, Liu W, et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine[J]. Transplantation, 2005，79(9)：1121-1127.
|
| 52 |
Patel JK, Coutance G, Loupy A, et al. Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients[J]. Am J Transplant, 2021，21(7)：2479-2488.
|